Wound care is multifaceted, and there is often scope for treatments to work in combination, with one enhancing the effect of the other. This is true of CAMPs, where adjuvant treatments can make all the difference in promoting and accelerating healing. This session will look at advanced technologies that can be used to enhance application and improve healing outcomes.

Use of adjuvant therapies to improve clinical outcomes with CAMPs

• Debridement (e.g. lasers, ultrasound, surgical plasma)

• Telemedicine

• Autologous point-of-care wound management system

The new local coverage determinations (LCDs) are expected to limit reimbursement of CAMPs for diabetic foot ulcers and venous leg ulcers to those with a strong supporting evidence base, and then for up to four applications only, unless medical necessity can be proven. This will have implications for both patients and health-care providers. This session will take a deep dive into the effect this will have not only on service provision, but also access.

To justify use of CAMPs on diabetic foot ulcers and venous leg ulcers, medical necessity will need to be demonstrated. This session will give practical advice on how to do this, based on accurate documentation of clinical assessment and implementation of standard of care.

The new LCD stipulates that coverage is only justified for CAMPs with a robust evidence base, with the implication being that current research data is neither extensive nor strong enough. But new research is making a strong case for the use of CAMPs. This talk will explore the latest evidence supporting the application of CAMPs on diabetic foot ulcers, outlining how much of a difference these advanced products are making to patient outcomes.

There are fears that the LCDs might also restrict coverage of CAMPs for tunnels, Mohs and other complex wound types. This session will give a comprehensive overview of the published and emerging research data on the use of CAMPs on these wounds, and outline what further research is needed.

It is feared that coverage might also be restricted for these wound types. This session will explore the likely impact, based on the existing research evidence for the use of CAMPs on these indications

Only access to CAMPs with a robust evidence base will be allowed by the new local coverage determinations (LCDs). But the evidence base for many CAMPs is highly variable, and is not necessarily an indication of their efficacy and cost-effectiveness. In this session, a panel will debate the minimum evidence requirements for all CAMPs going forward.

Given the likely CMS focus on research data for CAMPs, there is need for debate and consensus on what research methodologies will fit the bill. Here, following a panel discussion, the conversation will be opened up to attendees, with polling to generate agreement on the best options

To avoid payment denials, clawbacks and even audit, documentation must be thorough, demonstrating clinical necessity for CAMPs and compliance with the principles of best practice. This session will discuss how to facilitate this, with reference to case studies and scenarios.

Getting documentation right can be demanding. Artificial intelligence (AI) has scope to assist with this, automating some aspects of it. This session will provide examples of how AI has streamlined and improved the processes involved.

An in-depth look into how to use AI could improve record keeping and save time